Donor-matched mesenchymal stem cells from knee infrapatellar and subcutaneous adipose tissue of osteoarthritic donors display differential chondrogenic and osteogenic commitment

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Cell-based therapies have recently been proposed for the treatment of degenerative articular pathologies, such as early osteoarthritis, with an emphasis on autologous mesenchymal stem cells (MSCs), as an alternative to terminally differentiated cells. In this study, we performed a donor-matched comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee subcutaneous adipose tissue stem cells (ASCs), as appealing candidates for cell-based therapies that are easily accessible during surgery. IFP-MSCs and ASCs were obtained from 25 osteoarthritic patients undergoing total knee replacement and compared for their immunophenotype and differentiative potential. Undifferentiated IFP-MSCs and ASCs displayed the same immunophenotype, typical of MSCs (CD13+/CD29+/CD44+/CD73+/CD90+/CD105+/CD166+/CD31-/CD45-). IFP-MSCs and ASCs showed similar adipogenic potential, though undifferentiated ASCs had higher LEP expression compared to IFP-MSCs (p <0.01). Higher levels of calcified matrix (p <0.05) and alkaline phosphatase (p <0.05) in ASCs highlighted their superior osteogenic commitment compared to IFP-MSCs. Conversely, IFP-MSCs pellets showed greater amounts of glycosaminoglycans (p <0.01) and superior expression of ACAN (p <0.001), SOX9, COMP (p <0.001) and COL2A1 (p <0.05) compared to ASCs pellets, revealing a superior chondrogenic potential. This was also supported by lower COL10A1 (p <0.05) and COL1A1 (p <0.01) expression and lower alkaline phosphatase release (p <0.05) by IFP-MSCs compared to ASCs. The observed dissimilarities between IFP-MSCs and ASCs show that, despite expressing similar surface markers, MSCs deriving from different fat depots in the same surgical site possess specific features. Furthermore, the in vitro peculiar commitment of IFP-MSCs and ASCs from osteoarthritic donors towards the chondrogenic or osteogenic lineage may suggest a preferential use for cartilage and bone cell-based treatments, respectively.

Original languageEnglish
Pages (from-to)298-311
Number of pages14
JournalEuropean Cells and Materials
Volume27
Publication statusPublished - Apr 23 2014

Fingerprint

Subcutaneous Fat
Stem cells
Mesenchymal Stromal Cells
Adipose Tissue
Knee
Oils and fats
Tissue Donors
Tissue
Fats
Stem Cells
Phosphatases
Alkaline Phosphatase
Cell- and Tissue-Based Therapy
Knee prostheses
Cartilage
Pathology
Glycosaminoglycans
Surgery
Knee Replacement Arthroplasties
Bone

Keywords

  • Adipose tissue
  • Bone
  • Cartilage
  • Cell-based therapy
  • Infrapatellar fat pad
  • Mesenchymal stem cell
  • Osteoarthritis

ASJC Scopus subject areas

  • Cell Biology
  • Bioengineering
  • Biomedical Engineering
  • Biomaterials
  • Biochemistry

Cite this

@article{efc4df1fe71442879464bff71c35dfda,
title = "Donor-matched mesenchymal stem cells from knee infrapatellar and subcutaneous adipose tissue of osteoarthritic donors display differential chondrogenic and osteogenic commitment",
abstract = "Cell-based therapies have recently been proposed for the treatment of degenerative articular pathologies, such as early osteoarthritis, with an emphasis on autologous mesenchymal stem cells (MSCs), as an alternative to terminally differentiated cells. In this study, we performed a donor-matched comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee subcutaneous adipose tissue stem cells (ASCs), as appealing candidates for cell-based therapies that are easily accessible during surgery. IFP-MSCs and ASCs were obtained from 25 osteoarthritic patients undergoing total knee replacement and compared for their immunophenotype and differentiative potential. Undifferentiated IFP-MSCs and ASCs displayed the same immunophenotype, typical of MSCs (CD13+/CD29+/CD44+/CD73+/CD90+/CD105+/CD166+/CD31-/CD45-). IFP-MSCs and ASCs showed similar adipogenic potential, though undifferentiated ASCs had higher LEP expression compared to IFP-MSCs (p <0.01). Higher levels of calcified matrix (p <0.05) and alkaline phosphatase (p <0.05) in ASCs highlighted their superior osteogenic commitment compared to IFP-MSCs. Conversely, IFP-MSCs pellets showed greater amounts of glycosaminoglycans (p <0.01) and superior expression of ACAN (p <0.001), SOX9, COMP (p <0.001) and COL2A1 (p <0.05) compared to ASCs pellets, revealing a superior chondrogenic potential. This was also supported by lower COL10A1 (p <0.05) and COL1A1 (p <0.01) expression and lower alkaline phosphatase release (p <0.05) by IFP-MSCs compared to ASCs. The observed dissimilarities between IFP-MSCs and ASCs show that, despite expressing similar surface markers, MSCs deriving from different fat depots in the same surgical site possess specific features. Furthermore, the in vitro peculiar commitment of IFP-MSCs and ASCs from osteoarthritic donors towards the chondrogenic or osteogenic lineage may suggest a preferential use for cartilage and bone cell-based treatments, respectively.",
keywords = "Adipose tissue, Bone, Cartilage, Cell-based therapy, Infrapatellar fat pad, Mesenchymal stem cell, Osteoarthritis",
author = "S. Lopa and A. Colombini and D. Stanco and {de Girolamo}, L. and V. Sansone and M. Moretti",
year = "2014",
month = "4",
day = "23",
language = "English",
volume = "27",
pages = "298--311",
journal = "European Cells and Materials",
issn = "1473-2262",
publisher = "Swiss Society for Biomaterials",

}

TY - JOUR

T1 - Donor-matched mesenchymal stem cells from knee infrapatellar and subcutaneous adipose tissue of osteoarthritic donors display differential chondrogenic and osteogenic commitment

AU - Lopa, S.

AU - Colombini, A.

AU - Stanco, D.

AU - de Girolamo, L.

AU - Sansone, V.

AU - Moretti, M.

PY - 2014/4/23

Y1 - 2014/4/23

N2 - Cell-based therapies have recently been proposed for the treatment of degenerative articular pathologies, such as early osteoarthritis, with an emphasis on autologous mesenchymal stem cells (MSCs), as an alternative to terminally differentiated cells. In this study, we performed a donor-matched comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee subcutaneous adipose tissue stem cells (ASCs), as appealing candidates for cell-based therapies that are easily accessible during surgery. IFP-MSCs and ASCs were obtained from 25 osteoarthritic patients undergoing total knee replacement and compared for their immunophenotype and differentiative potential. Undifferentiated IFP-MSCs and ASCs displayed the same immunophenotype, typical of MSCs (CD13+/CD29+/CD44+/CD73+/CD90+/CD105+/CD166+/CD31-/CD45-). IFP-MSCs and ASCs showed similar adipogenic potential, though undifferentiated ASCs had higher LEP expression compared to IFP-MSCs (p <0.01). Higher levels of calcified matrix (p <0.05) and alkaline phosphatase (p <0.05) in ASCs highlighted their superior osteogenic commitment compared to IFP-MSCs. Conversely, IFP-MSCs pellets showed greater amounts of glycosaminoglycans (p <0.01) and superior expression of ACAN (p <0.001), SOX9, COMP (p <0.001) and COL2A1 (p <0.05) compared to ASCs pellets, revealing a superior chondrogenic potential. This was also supported by lower COL10A1 (p <0.05) and COL1A1 (p <0.01) expression and lower alkaline phosphatase release (p <0.05) by IFP-MSCs compared to ASCs. The observed dissimilarities between IFP-MSCs and ASCs show that, despite expressing similar surface markers, MSCs deriving from different fat depots in the same surgical site possess specific features. Furthermore, the in vitro peculiar commitment of IFP-MSCs and ASCs from osteoarthritic donors towards the chondrogenic or osteogenic lineage may suggest a preferential use for cartilage and bone cell-based treatments, respectively.

AB - Cell-based therapies have recently been proposed for the treatment of degenerative articular pathologies, such as early osteoarthritis, with an emphasis on autologous mesenchymal stem cells (MSCs), as an alternative to terminally differentiated cells. In this study, we performed a donor-matched comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee subcutaneous adipose tissue stem cells (ASCs), as appealing candidates for cell-based therapies that are easily accessible during surgery. IFP-MSCs and ASCs were obtained from 25 osteoarthritic patients undergoing total knee replacement and compared for their immunophenotype and differentiative potential. Undifferentiated IFP-MSCs and ASCs displayed the same immunophenotype, typical of MSCs (CD13+/CD29+/CD44+/CD73+/CD90+/CD105+/CD166+/CD31-/CD45-). IFP-MSCs and ASCs showed similar adipogenic potential, though undifferentiated ASCs had higher LEP expression compared to IFP-MSCs (p <0.01). Higher levels of calcified matrix (p <0.05) and alkaline phosphatase (p <0.05) in ASCs highlighted their superior osteogenic commitment compared to IFP-MSCs. Conversely, IFP-MSCs pellets showed greater amounts of glycosaminoglycans (p <0.01) and superior expression of ACAN (p <0.001), SOX9, COMP (p <0.001) and COL2A1 (p <0.05) compared to ASCs pellets, revealing a superior chondrogenic potential. This was also supported by lower COL10A1 (p <0.05) and COL1A1 (p <0.01) expression and lower alkaline phosphatase release (p <0.05) by IFP-MSCs compared to ASCs. The observed dissimilarities between IFP-MSCs and ASCs show that, despite expressing similar surface markers, MSCs deriving from different fat depots in the same surgical site possess specific features. Furthermore, the in vitro peculiar commitment of IFP-MSCs and ASCs from osteoarthritic donors towards the chondrogenic or osteogenic lineage may suggest a preferential use for cartilage and bone cell-based treatments, respectively.

KW - Adipose tissue

KW - Bone

KW - Cartilage

KW - Cell-based therapy

KW - Infrapatellar fat pad

KW - Mesenchymal stem cell

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84899148742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899148742&partnerID=8YFLogxK

M3 - Article

C2 - 24760577

AN - SCOPUS:84899148742

VL - 27

SP - 298

EP - 311

JO - European Cells and Materials

JF - European Cells and Materials

SN - 1473-2262

ER -